GCI Health announced the addition of Ryan Kuresman, Group Senior Vice President, to expand and lead the agency’s health policy and public affairs offering out of the GCI Health’s Washington, DC, office. In this role, Ryan will be responsible for elevating GCI Health’s ability to engage with and communicate to policymakers and influencers and health advocacy stakeholders. He brings significant expertise on a range of issues driving changes in policy and business behavior in the health space, including market access, competition, access and affordability, innovation, tort reform, drug pricing, patent and intellectual property, litigation communications and public health.
Over the last few years, with a heavy focus on access, public affairs and advocacy, GCI Health made the decision to expand this offering to further help the agency’s clients that are seeking to proactively and reactively engage on public affairs and policy-centered challenges and opportunities, with capabilities to shape communications campaigns in areas that include business-critical reputational challenges, health policy thought leadership, stakeholder engagement, coalition building and crisis response.
“The expectations placed on healthcare companies in this current and highly challenging environment has dynamically changed, and the ways they engage, partner and support patients, providers, health advocates and policymakers are as critical to their reputation as it is to business outcomes,” said Kuresman. “As we head toward the election in November, and in the midst of a global public health crisis, transparency, a willingness to partner with government and readiness to bring forward proactive solutions-based efforts have never been more important for companies, industry associations and advocacy leaders across the healthcare ecosystem. I am thrilled to join GCI Health and work with some of the best health communicators in the business to further integrate a public affairs and health policy mindset into the incredible work we are doing.”
Most recently, Ryan was at Edelman, where he worked on complex policy debates and business-critical assignments at the local, national and international levels. Ryan’s broader experience includes work with biopharmaceutical companies, health industry trade associations, patient advocacy coalitions, biomedical research institutes and science-based consumer healthcare companies with a focus on managing their policy, issues and reputational profiles.